Published in J Natl Cancer Inst on May 27, 2008
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med (2011) 5.77
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
ETS gene fusions in prostate cancer. Nat Rev Urol (2009) 2.43
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One (2009) 2.21
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Prostate cancer genomics: towards a new understanding. Nat Rev Genet (2008) 2.08
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun (2014) 1.84
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov (2014) 1.58
Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat Commun (2013) 1.57
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev (2009) 1.51
ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clin Cancer Res (2015) 1.50
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol (2011) 1.39
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 1.35
Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci U S A (2010) 1.32
Conquering the complex world of human septins: implications for health and disease. Clin Genet (2010) 1.29
TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer (2011) 1.26
SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia (2014) 1.23
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med (2016) 1.22
Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res (2013) 1.16
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia (2010) 1.14
Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med (2012) 1.06
An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med (Berl) (2009) 1.05
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol (2013) 1.03
Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer (2010) 1.03
Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One (2014) 1.01
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer (2009) 1.00
ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology (2010) 0.97
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst (2013) 0.97
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression. BMC Cancer (2010) 0.97
ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res (2013) 0.94
Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget (2015) 0.94
Statistical assessment of crosstalk enrichment between gene groups in biological networks. PLoS One (2013) 0.94
Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One (2011) 0.94
TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene (2014) 0.94
The oncogene ERG: a key factor in prostate cancer. Oncogene (2015) 0.93
Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. Carcinogenesis (2013) 0.92
Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PLoS One (2011) 0.92
PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Res (2013) 0.92
SEPT9_v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation. J Biol Chem (2009) 0.91
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci U S A (2012) 0.91
The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Mol Oncol (2013) 0.89
Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer. PLoS One (2014) 0.87
Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res (2010) 0.86
Algebraic comparison of partial lists in bioinformatics. PLoS One (2012) 0.85
Genome-wide expression analysis of recently processed formalin-fixed paraffin embedded human prostate tissues. Prostate (2009) 0.84
Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate (2012) 0.84
MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma. J Exp Clin Cancer Res (2015) 0.83
Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncol Lett (2013) 0.83
Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers. Br J Cancer (2013) 0.82
ETS rearrangements in prostate cancer. Asian J Androl (2012) 0.82
Markers for detection of prostate cancer. Cancers (Basel) (2010) 0.82
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nat Commun (2015) 0.81
Decreased expression of stromal estrogen receptor α and β in prostate cancer. Am J Transl Res (2014) 0.81
Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl (2016) 0.81
ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer. PLoS One (2013) 0.81
Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status. Am J Epidemiol (2015) 0.81
miR-539 inhibits prostate cancer progression by directly targeting SPAG5. J Exp Clin Cancer Res (2016) 0.79
ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. Mol Clin Oncol (2014) 0.79
Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks. Adv Bioinformatics (2012) 0.79
Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis (2015) 0.79
Gene signatures related to HAI response following influenza A/H1N1 vaccine in older individuals. Heliyon (2016) 0.78
Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression. Cancer Res (2016) 0.78
Drug repositioning discovery for early- and late-stage non-small-cell lung cancer. Biomed Res Int (2014) 0.78
Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia (2016) 0.77
Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. Cancer Med (2016) 0.77
A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function. Am J Respir Cell Mol Biol (2014) 0.77
Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control (2012) 0.77
ERG expression in prostate cancer: biological relevance and clinical implication. J Cancer Res Clin Oncol (2015) 0.76
Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. Br J Cancer (2016) 0.76
Molecular subtyping of prostate cancer. Curr Opin Urol (2016) 0.76
[Dangerous liaisons in prostate cancer. Clinical and biological implications of recurrent gene fusions]. Pathologe (2010) 0.76
Prostate cancer stem cells: molecular characterization for targeted therapy. Asian J Androl (2012) 0.76
Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data. Asian J Androl (2012) 0.76
Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors. Clin Epigenetics (2015) 0.76
Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer. PLoS Comput Biol (2016) 0.76
Reproducible detection of disease-associated markers from gene expression data. BMC Med Genomics (2016) 0.75
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. Yonsei Med J (2016) 0.75
CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer therapeutics. Eur Biophys J (2016) 0.75
Language workbench user interfaces for data analysis. PeerJ (2015) 0.75
Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. PLoS One (2015) 0.75
Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. Oncotarget (2016) 0.75
Elevated oestrogen receptor splice variant ERαΔ5 expression in tumour-adjacent hormone-responsive tissue. Int J Environ Res Public Health (2010) 0.75
Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res (2016) 0.75
Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness. Cell Adh Migr (2016) 0.75
Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. Mol Cell Endocrinol (2016) 0.75
Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. Int J Mol Sci (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA (1992) 4.31
Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA (1997) 3.80
Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res (1999) 3.79
Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia (2007) 3.06
Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol (2004) 3.04
Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A (2004) 2.64
How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol (2006) 2.21
Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res (2000) 2.16
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia (2007) 1.75
Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett (2004) 1.45
Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol (1999) 1.41
Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate (2003) 1.36
Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet (1989) 1.26
The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol (2005) 1.20
Identification of the human Mnk2 gene (MKNK2) through protein interaction with estrogen receptor beta. Genomics (2000) 1.14
Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate (2001) 1.11
Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab (2001) 1.00
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell (2005) 14.32
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell (2008) 14.18
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Model-based analysis of tiling-arrays for ChIP-chip. Proc Natl Acad Sci U S A (2006) 13.68
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet (2009) 12.96
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med (2008) 12.41
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81
Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science (2010) 9.78
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med (2010) 8.71
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49